Spectral Diagnostics (OTCMKTS:EDTXF) Issues Quarterly Earnings Results, Meets Expectations

Key Points

• EPS met expectations: Spectral Diagnostics reported quarterly EPS of ($0.01), matching the consensus, but revenue was $0.28 million versus analyst estimates of $0.54 million, a notable miss.
• Stock and valuation snapshot: Shares fell to $1.02 on light volume (100 shares vs. a 8,680 average), with a market cap of $298.41 million and a negative P/E of -9.27.
• Business focus: The company develops septic shock diagnostics and therapies, including the Endotoxin Activity Assay and Polymyxin B Hemoperfusion devices.

Spectral Diagnostics (OTCMKTS:EDTXF - Get Free Report) issued its earnings results on Thursday. The company reported ($0.01) earnings per share for the quarter, meeting the consensus estimate of ($0.01), reports. The firm had revenue of $0.28 million during the quarter, compared to analyst estimates of $0.54 million.

Spectral Diagnostics Price Performance

Shares of EDTXF traded down $0.04 during midday trading on Friday, reaching $1.02. The stock had a trading volume of 100 shares, compared to its average volume of 8,680. Spectral Diagnostics has a 1-year low of $0.47 and a 1-year high of $1.31. The company's fifty day simple moving average is $0.97 and its two-hundred day simple moving average is $1.00. The company has a market cap of $298.41 million, a price-to-earnings ratio of -9.27 and a beta of 0.04.

About Spectral Diagnostics

Spectral Medical Inc focuses on the development and commercialization of products for the treatment of septic shock in the United States, Italy, Ireland, and internationally. The company markets Endotoxin Activity Assay, a rapid in vitro diagnostic test for the detection of components of gram negative bacterial cell wall; and Polymyxin B Hemoperfusion, a therapeutic hemoperfusion device that removes endotoxin from the bloodstream. It also develops and manufactures monoclonal and polyclonal antibodies, recombinant cardiac proteins, and calibrators for use in the research and development, as well as products that are manufactured by other diagnostic companies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.